Medivir AB (STO:MVIRB) on Wednesday reported loss after tax of SEK39.8m, or SEK1.48 per share, for the second quarter 2016, from April 2016 to June 2016.
This was a decline over profit after tax of SEK64.1m, or EPS of SEK2.19, in Q2 2015.
Net turnover for the quarter totalled SEK81.3m, of which SEK24.2m comprised of royalties for simeprevir. This was in comparison with net turnover of SEK245.8m in Q2 2015, of which SEK165.6m comprised royalties for simeprevir.
For the quarter, revenues from Medivir's own pharmaceutical sales totalled SEK50.1m, of which SEK5.6m were from sales of OLYSIO and SEK44.5m were from sales of other pharmaceuticals.
In comparison, revenues from Medivir's own pharmaceutical sales for Q2 2015 totalled SEK55.1m, of which SEK13.2m were from sales of OLYSIO and SEK41.9m were from sales of other pharmaceuticals.
Medivir is a research based pharmaceutical company with a research focus on oncology and infectious diseases.
(EUR1.00=SEK9.48)
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government